BEVESPI AEROSPHERE
LAMALABA MDI
Glycopyrrolate / Formoterol fumarate · AstraZeneca
Active Medication & Mechanism
- Glycopyrrolate LAMA9 mcg per actuation
Long-acting muscarinic antagonist. Blocks M3 muscarinic receptors on airway smooth muscle, preventing acetylcholine-induced bronchoconstriction.
- Formoterol fumarate LABA4.8 mcg per actuation
Long-acting beta2-adrenergic agonist with rapid onset of action. Stimulates beta2-receptors, increasing cAMP and relaxing airway smooth muscle.
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 9/4.8 mcg | Adults (≥18 years) | 2 inhalations twice daily (morning and evening) Long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. | 36/19.2 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Bevespi Aerosphere is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious events. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not indicated for relief of acute bronchospasm. Use a SABA. |